Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.

Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC

Open source

DOI: 10.1016/j.esmoop.2024.103697
Published: 2024 Sep
Container: ESMO open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2024.103697,
  title = {Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.},
  author = {Rugo HS and Oliveira M and Howell SJ and Dalenc F and Cortes J and Gomez HL and Hu X and Jhaveri KL and Krivorotko P and Loibl S and Morales Murillo S and Nowecki Z and Okera M and Park YH and Sohn J and Toi M and Iwata H and Yousef S and Zhukova L and Logan J and Twomey K and Khatun M and D'Cruz CM and Turner NC},
  year = {2024},
  journal = {ESMO open},
  doi = {10.1016/j.esmoop.2024.103697},
  url = {https://doi.org/10.1016/j.esmoop.2024.103697}
}

RIS

TY  - JOUR
TI  - Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
AU  - Rugo HS
AU  - Oliveira M
AU  - Howell SJ
AU  - Dalenc F
AU  - Cortes J
AU  - Gomez HL
AU  - Hu X
AU  - Jhaveri KL
AU  - Krivorotko P
AU  - Loibl S
AU  - Morales Murillo S
AU  - Nowecki Z
AU  - Okera M
AU  - Park YH
AU  - Sohn J
AU  - Toi M
AU  - Iwata H
AU  - Yousef S
AU  - Zhukova L
AU  - Logan J
AU  - Twomey K
AU  - Khatun M
AU  - D'Cruz CM
AU  - Turner NC
PY  - 2024
JO  - ESMO open
DO  - 10.1016/j.esmoop.2024.103697
UR  - https://doi.org/10.1016/j.esmoop.2024.103697
ER  -

APA

HS, R., M, O., SJ, H., F, D., J, C., HL, G., X, H., KL, J., P, K., S, L., S, M. M., Z, N., M, O., YH, P., J, S., M, T., H, I., S, Y., L, Z., J, L., K, T., M, K., CM, D., & NC, T. (2024). Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.. ESMO open. https://doi.org/10.1016/j.esmoop.2024.103697

Source records

pubmed · retrieved 2026-09-26T11:05:58.555Z